Achieve Life Sciences

Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of cytisinicline for smoking cessation. Its products includes cytisine, a plant-based alkaloid with a binding affinity to the nicotinic acetylcholine receptor. The company was founded in October 1991 and is headquartered in Vancouver, Canada.

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Earnings data Q4 2025

Earnings data Q1 2026

Achieve Life Sciences reports positive trial results, faces funding challenges

Achieve Life Sciences demonstrated promising results in vaping cessation with cytisinicline treatment, showing significant benefits and a strong market demand for cessation solutions.
While facing challenges of increasing expenses and a net loss in Q1 2023, the company's cash balance and upcoming trials provide opportunities for growth and market expansion.
The company's strategic initiatives, including the Board of Directors refresh, position Achieve Life Sciences for future success in addressing the vaping cessation market.

Achieve Life Sciences advances cytisinicline trials, targets FDA approval

Achieve Life Sciences is making significant progress with cytisinicline, despite facing financial losses. Strategic initiatives and a proactive approach to FDA engagement position the company well for future growth and NDA submission.

Achieve Life Sciences reports improved Q3 performance and eyes NDA submission

Achieve Life Sciences shows financial improvement and promising results in the cytisinicline program for smoking cessation. Engaging with the FDA for NDA submission and seeking commercial partners are key priorities. Challenges include finalizing partnerships and defining regulatory pathways, while opportunities exist in global partnerships and public health impact.

Achieve Life Sciences excels in 2023, poised for growth and innovation

Achieve Life Sciences demonstrated strong performance in achieving key milestones, securing financing, and presenting positive trial results in 2023.
While facing challenges in regulatory discussions and trial completion, the company's strategic strengths in financial stability, regulatory compliance, and innovation position it well for future growth.
Opportunities lie in market expansion, partnerships, and visibility enhancement through continued FDA engagement, commercial collaborations, and industry participation.

Achieve Life Sciences excels in trials and secures funding for growth

Achieve Life Sciences demonstrated strong operational and financial performance with positive trial outcomes and strategic financing.
Regulatory advancements and successful trial results underscore the company's credibility and potential for market expansion.
Challenges in recruitment, regulatory compliance, and financial management require attention for sustained growth and success.

Achieve Life Sciences advances vaping cessation program with FDA breakthrough

Achieve Life Sciences showcased progress in its Cytisinicline Development Program and financial stability through debt refinancing.
While facing challenges in trial enrollment and regulatory requirements, the company remains optimistic about future milestones.
The FDA breakthrough therapy designation and focus on public health underscore Achieve Life Sciences' commitment to addressing nicotine dependence.

Achieve Life Sciences advances cytisinicline for nicotine dependence treatment

Achieve Life Sciences made notable progress in 2024 towards NDA submission for cytisinicline, with a focus on commercialization and strategic partnerships. The company's financial position is stable, and management is optimistic about the drug's potential in addressing nicotine dependence.

Achieve Life Sciences advances cytisinicline NDA submission amid financial growth

Achieve Life Sciences is making significant strides towards NDA submission for cytisinicline, backed by positive trial results and financial resources. While facing financial challenges and regulatory complexities, the company is exploring partnerships and market opportunities to drive the success of cytisinicline.

Achieve Life Sciences excels in Q2 2025, poised for industry transformation

Achieve Life Sciences demonstrated strong performance in Q2 2025, underpinned by transformative milestones, solid financials, and strategic partnerships. While challenges in commercial launch execution may arise, the company's focus on regulatory excellence and market readiness presents significant growth opportunities. Overall, Achieve is poised for success in reshaping the smoking cessation landscape.

Achieve Life Sciences excels in Q3, poised for market leadership

Achieve Life Sciences demonstrated strong performance and strategic advancements in Q3 2025. While facing challenges in a competitive landscape, Achieve's focus on innovation and market needs provides opportunities for growth. The company's financial stability and leadership additions position Achieve well for future success. Overall, Achieve's progress with cytisinicline and FDA milestones set a positive trajectory for the company.